Explore our published results, updates, events, publications, and more
[{"title":"Spur Therapeutics Announces Development Candidate in Parkinson\u2019s Disease Gene Therapy Program","slug":"spur-therapeutics-announces-development-candidate-in-parkinsons-disease-gene-therapy-program","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/12\/03\/2990425\/0\/en\/Spur-Therapeutics-Announces-Development-Candidate-in-Parkinson-s-Disease-Gene-Therapy-Program.html","date":"12.03.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in Upcoming Investor Conferences","slug":"spur-therapeutics-to-participate-in-upcoming-investor-conferences","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/11\/19\/2983555\/0\/en\/Spur-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","date":"11.19.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in B. Riley Securities\u2019 Next-Gen Tissue Delivery Modalities Virtual Summit","slug":"spur-therapeutics-to-participate-in-b-riley-securities-next-gen-tissue-delivery-modalities-virtual-summit","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/11\/07\/2976597\/0\/en\/Spur-Therapeutics-to-Participate-in-B-Riley-Securities-Next-Gen-Tissue-Delivery-Modalities-Virtual-Summit.html","date":"11.07.2024","format":"Press Release"},{"title":"Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)","slug":"spur-therapeutics-publishes-preclinical-proof-of-concept-data-for-sbt101-its-gene-therapy-candidate-in-adrenomyeloneuropathy-amn","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/31\/2972535\/0\/en\/Spur-Therapeutics-Publishes-Preclinical-Proof-of-Concept-Data-for-SBT101-its-Gene-Therapy-Candidate-in-Adrenomyeloneuropathy-AMN.html","date":"10.31.2024","format":"Press Release"},{"title":"Spur Therapeutics Showcases Positive New Data from Phase 1\/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress","slug":"spur-therapeutics-showcases-positive-new-data-from-phase-1-2-galileo-1-trial-of-flt201-its-novel-gene-therapy-candidate-for-gaucher-disease-in-oral-presentation-at-esgct-31st-annual-congress","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/23\/2967469\/0\/en\/Spur-Therapeutics-Showcases-Positive-New-Data-from-Phase-1-2-GALILEO-1-Trial-of-FLT201-Its-Novel-Gene-Therapy-Candidate-for-Gaucher-Disease-in-Oral-Presentation-at-ESGCT-31st-Annua.html","date":"10.23.2024","format":"Press Release"},{"title":"Spur\u2019s ESGCT presentation on new clinical data for FLT201 in Gaucher Disease","slug":"spurs-esgct-presentation-on-new-clinical-data-for-flt201-in-gaucher-disease","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Spur-Therapeutics-ESGCT-Rome-2024-FLT201-Presentation-10-23-24.pdf","date":"10.23.2024","format":"Press Release"},{"title":"Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress","slug":"spur-therapeutics-announces-oral-presentation-highlighting-new-clinical-data-for-flt201-in-gaucher-disease-at-upcoming-european-society-of-gene-cell-therapy-esgct-31st-annual-congress","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/10\/03\/2957650\/0\/en\/Spur-Therapeutics-Announces-Oral-Presentation-Highlighting-New-Clinical-Data-for-FLT201-in-Gaucher-Disease-at-Upcoming-European-Society-of-Gene-Cell-Therapy-ESGCT-31st-Annual-Congr.html","date":"10.03.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in Chardan\u2019s 8th Annual Genetic Medicines Conference","slug":"spur-therapeutics-to-participate-in-chardans-8th-annual-genetic-medicines-conference","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/09\/23\/2951332\/0\/en\/Spur-Therapeutics-to-Participate-in-Chardan-s-8th-Annual-Genetic-Medicines-Conference.html","date":"09.23.2024","format":"Press Release"},{"title":"Spur Therapeutics Completes Enrollment in Phase 1\/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial","slug":"spur-therapeutics-completes-enrollment-in-phase-1-2-galileo-1-trial-of-flt201-in-gaucher-disease-and-selects-dose-for-planned-phase-3-trial","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/08\/2909533\/0\/en\/Spur-Therapeutics-Completes-Enrollment-in-Phase-1-2-GALILEO-1-Trial-of-FLT201-in-Gaucher-Disease-and-Selects-Dose-for-Planned-Phase-3-Trial.html","date":"07.08.2024","format":"Press Release"},{"title":"Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson\u2019s Disease Research Program","slug":"spur-therapeutics-presents-promising-new-data-from-its-gba1-parkinsons-disease-research-program","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/01\/2906591\/0\/en\/Spur-Therapeutics-Presents-Promising-New-Data-from-its-GBA1-Parkinson-s-Disease-Research-Program.html","date":"07.01.2024","format":"Press Release"},{"title":"Spur Therapeutics to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference","slug":"spur-therapeutics-to-participate-in-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/20\/2901534\/0\/en\/Spur-Therapeutics-to-Participate-in-the-H-C-Wainwright-5th-Annual-Neuro-Perspectives-Virtual-Conference.html","date":"06.20.2024","format":"Press Release"},{"title":"Spur Therapeutics (Formerly Freeline) Announces New Name and Brand","slug":"spur-therapeutics-formerly-freeline-announces-new-name-and-brand","hyperlink":"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/17\/2899496\/0\/en\/Spur-Therapeutics-Formerly-Freeline-Announces-New-Name-and-Brand.html","date":"06.17.2024","format":"Press Release"},{"title":"Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1","slug":"results-from-galileo-1-a-first-in-human-clinical-trial-of-flt201-gene-therapy-in-patients-with-gaucher-disease-type-1","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GALILEO-1-Results-ASGCT2024-Final-Presentation.pdf","date":"05.09.2024","format":"Presentation"},{"title":"GBA1-Linked Parkinson\u2019s Disease AAV Gene Therapy (ASGCT 2024)","slug":"gba1-linked-parkinsons-disease-aav-gene-therapy-asgct-2024","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GBA1-PD-ASGCT2024-Final-Presentation.pdf","date":"05.09.2024","format":"Presentation"},{"title":"Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1 (ESGCT 2023)","slug":"results-from-galileo-1-a-first-in-human-clinical-trial-of-flt201-gene-therapy-in-patients-with-gaucher-disease-type-1-esgct-2023","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/Freeline-GALILEO-1-Results-ASGCT2024-Final-Presentation-1.pdf","date":"10.25.2023","format":"Presentation"},{"title":"Design of GALILEO-1, a Phase 1\/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (World Symposium 2022)","slug":"design-of-galileo-1-a-phase-1-2-safety-and-efficacy-study-of-flt201-in-adult-patients-with-gaucher-disease-type-1-world-symposium-2022","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/worldsymposium_2022_galileo1_hughes-et-al.pdf","date":"02.10.2022","format":"Presentation"},{"title":"FLT201, a Novel Investigational AAV-Mediated Gene Therapy Candidate for Gaucher Disease Type 1","slug":"flt201-a-novel-investigational-aav-mediated-gene-therapy-candidate-for-gaucher-disease-type-1","hyperlink":"https:\/\/player.vimeo.com\/video\/547871323","date":"05.11.2021","format":"Presentation"},{"title":"FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues (World Symposium 2021)","slug":"flt201-an-aav-mediated-gene-therapy-for-type-1-gaucher-disease-designed-to-target-difficult-to-reach-tissues-world-symposium-2021","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/flt201-an-aav-mediated-gene-therapy-for-type-1-gaucher-disease-designed.pdf","date":"02.08.2021","format":"Presentation"},{"title":"Generation of \u03b2-Glucocerebrosidase Variants with Increased Half-life in Human Plasma for Liver Directed AAV Gene Therapy for the Treatment of Type 1 Gaucher Disease (World Symposium 2021)","slug":"generation-of-%ce%b2-glucocerebrosidase-variants-with-increased-half-life-in-human-plasma-for-liver-directed-aav-gene-therapy-for-the-treatment-of-type-1-gaucher-disease-world-symposium-2021","hyperlink":"https:\/\/spurtherapeutics.com\/wp-content\/uploads\/generation-of-\u03b2-glucocerebrosidase-variants-with-increased-half-life-in-human-plasma-for.pdf","date":"02.08.2021","format":"Presentation"},{"title":"Liver directed AAV gene therapy to treat Gaucher disease (Molecular Genetics and Metabolism, 2019)","slug":"liver-directed-aav-gene-therapy-to-treat-gaucher-disease-molecular-genetics-and-metabolism-2019","hyperlink":"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1096719218310333","date":"02.04.2019","format":"Publication"},{"title":"Explore earlier archived updates and announcements.","slug":"explore-earlier-archived-updates-and-announcements","hyperlink":"https:\/\/www.globenewswire.com\/en\/search\/keyword\/Freeline%252520Therapeutics%252520Holdings%252520plc\/tag\/freeline%252520therapeutics?pageSize=10","date":"Archive","format":"Press Release"}]
Featured
Learn more about Spur, our mission, and our product candidates.
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress